Trajectories of sickness absence and disability pension before and after opioid initiation for noncancer pain: a 10-year population-based study.
Journal
Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
entrez:
23
4
2019
pubmed:
23
4
2019
medline:
13
2
2020
Statut:
ppublish
Résumé
Chronic noncancer pain is a leading cause of sickness absence (SA) and disability pension (DP). The objectives of this study were to identify trajectories of SA/DP before and after strong and weak opioid initiation for noncancer pain and the factors associated with these trajectories. A longitudinal population-based study of 201,641 people (24-59 years) without cancer who initiated opioid analgesics in 2009 in Sweden was conducted. Trajectories of net annual SA/DP days in the 5 years before/after opioid initiation were estimated with group-based trajectory modelling. Multinomial logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for factors associated with trajectory groups. Among the 6.9% of people initiating strong opioids, 12.5% had persistent high SA/DP (estimated 320 days/year) before and after opioid initiation and 72.9% had persistent low/minimum SA/DP (estimated 30 days/year). Approximately 8.6% of people had increasing SA/DP, and 6.1% had decreasing SA/DP after opioid initiation, although this seemed to reflect continuation of preinitiation patterns. Trajectories were similar at lower SA/DP days/year among those initiating weak opioids. Persistent high SA/DP among strong opioid initiators were associated with ≥5 comorbidities (OR = 8.72, 95% CI 5.61-13.56), ≤9 years of education (OR = 5.83, 95% CI 4.84-7.03), and previous use of antidepressants (OR = 4.57, 95% CI 3.89-5.37) and antipsychotics (OR = 4.49, 95% CI 2.93-6.88). Three-quarters of people initiating opioids for noncancer pain had persistent low/minimum levels of SA/DP 5 years before and after initiation. Increasing and decreasing SA/DP after opioid initiation seemed to reflect a continuation of preinitiation patterns. Our findings highlight the complex range of sociodemographic and medication-related factors associated with persistent SA/DP.
Identifiants
pubmed: 31009421
doi: 10.1097/j.pain.0000000000001500
pii: 00006396-201905000-00023
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1224-1233Références
Allebeck P, Mastekaasa A. Swedish Council on Technology Assessment in Health Care (SBU). Chapter 3. Causes of sickness absence: research approaches and explanatory models. Scand J Public Health Suppl 2004;63:36–43.
Allebeck P, Mastekaasa A. Swedish Council on Technology Assessment in Health Care (SBU). Chapter 5. Risk factors for sick leave—general studies. Scand J Public Health Suppl 2004;63:49–108.
Andruff H, Carraro N, Thompson A, Gaudreau P, Louvet B. Latent class growth modelling: a tutorial. Tutor Quant Methods Psychol 2009;5:11–24.
Bergman B, Hodell T, Kopparhed U. Regional divisions in Sweden on 1 January 2003. Part 1. Stockholm: Statistics Sweden, Report no. MIS 2003:1, 2003.
Bergstrom G, Bodin L, Bertilsson H, Jensen IB. Risk factors for new episodes of sick leave due to neck or back pain in a working population. A prospective study with an 18-month and a three-year follow-up. Occup Environ Med 2007;64:279–87.
Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, Hao W, Johnson DT, Mohar A, Pavadia J, Samak AK, Sipp W, Sumyai V, Suryawati S, Toufiq J, Yans R, Mattick RP. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet 2016;387:1644–56.
Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287–333.
Burke DS. Forecasting the opioid epidemic. Science 2016;354:529.
Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015;162:276–86.
Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ 2015;350:g6380.
Dhingra L, Ahmed E, Shin J, Scharaga E, Magun M. Cognitive effects and sedation. Pain Med 2015;16(suppl 1):S37–S43.
Dorner TE, Alexanderson K, Svedberg P, Tinghog P, Ropponen A, Mittendorfer-Rutz E. Synergistic effect between back pain and common mental disorders and the risk of future disability pension: a nationwide study from Sweden. Psychol Med 2016;46:425–36.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 2016;315:1624–45.
Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, Riley J, Dahan A. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol 2013;75:60–78.
Duenas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res 2016;9:457–67.
Enthoven WTM, Roelofs PD, Koes BW. NSAIDs for chronic low back pain. JAMA 2017;317:2327–8.
Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012;13:715–24.
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743–800.
Gureje O, Von Korff M, Kola L, Demyttenaere K, He Y, Posada-Villa J, Lepine JP, Angermeyer MC, Levinson D, de Girolamo G, Iwata N, Karam A, Guimaraes Borges GL, de Graaf R, Browne MO, Stein DJ, Haro JM, Bromet EJ, Kessler RC, Alonso J. The relation between multiple pains and mental disorders: results from the World Mental Health Surveys. PAIN 2008;135:82–91.
Hansson T, Jensen I. Swedish Council on Technology Assessment in Health Care (SBU). Chapter 6. Sickness absence due to back and neck disorders. Scand J Public Health Suppl 2004;63:109–51.
Haukka E, Kaila-Kangas L, Ojajarvi A, Miranda H, Karppinen J, Viikari-Juntura E, Heliovaara M, Leino-Arjas P. Pain in multiple sites and sickness absence trajectories: a prospective study among Finns. PAIN 2013;154:306–12.
Hauser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep 2017;2:e599.
Hubertsson J, Englund M, Hallgarde U, Lidwall U, Lofvendahl S, Petersson IF. Sick leave patterns in common musculoskeletal disorders—a study of doctor prescribed sick leave. BMC Musculoskelet Disord 2014;15:176.
Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol 2016;82:255–67.
Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med 2012;6:e41–47.
Khan TW, Imani F. The management of chronic pain; caught between a rock and a hard place: the case for a renewed focus on provider, patient, and payer education. Anesth Pain Med 2017;7:e40951.
Kidner CL, Mayer TG, Gatchel RJ. Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders. J Bone Joint Surg Am 2009;91:919–27.
Lalic S, Gisev N, Bell JS, Korhonen MJ, Ilomaki J. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia. Br J Clin Pharmacol 2018;84:1267–78.
Lu CY, Barratt J, Vitry A, Roughead E. Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. J Clin Epidemiol 2011;64:223–8.
Maclaren JE, Gross RT, Sperry JA, Boggess JT. Impact of opioid use on outcomes of functional restoration. Clin J Pain 2006;22:392–8.
Methods of treating chronic pain [in Swedish]. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care (SBU); 2006. SBU Report No: 177/1+2.
Murphy JL, Clark ME, Banou E. Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. Clin J Pain 2013;29:109–17.
Nagin DS. Analyzing developmental trajectories: a semiparametric, group-based approach. Psychol Methods 1999;4:139–57.
Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010;6:109–38.
Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf 2016;25:733–7.
Pedersen P, Lund T, Lindholdt L, Nohr EA, Jensen C, Sogaard HJ, Labriola M. Labour market trajectories following sickness absence due to self-reported all cause morbidity—a longitudinal study. BMC Public Health 2016;16:337.
Phillips CJ. The cost and burden of chronic pain. Rev Pain 2009;3:2–5.
Rodriguez-Blazquez C, Damian J, Andres-Prado MJ, Almazan-Isla J, Alcalde-Cabero E, Forjaz MJ, Castellote JM, Gonzalez-Enriquez J, Martinez-Martin P, Comin M, de Pedro-Cuesta J. Associations between chronic conditions, body functions, activity limitations and participation restrictions: a cross-sectional approach in Spanish non-clinical populations. BMJ Open 2016;6:e010446.
Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain 2015;19:59–66.
Saragiotto BT, Machado GC, Ferreira ML, Pinheiro MB, Abdel Shaheed C, Maher CG. Paracetamol for low back pain. Cochrane Database Syst Rev 2016;6:CD012230.
Sickness absence in the Nordic Countries. Copenhagen, Denmark: Nordic Social Statistical Committee 59; 2015. Available at: http://norden.diva-portal.org/smash/get/diva2:811504/FULLTEXT06.pdf. Accessed October 19, 2018.
Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009;12:679–84.
Social insurance in figures 2017. Stockholm, Sweden: Försäkringskassan (Swedish Social Insurance Agency), 2017.
Soderberg KC, Laflamme L, Moller J. Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden. CNS Drugs 2013;27:155–61.